Home > Insider Trading > Filing (0001209191-21-031670)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1357874	Precision Biosciences Inc	DTIL	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1769887	R. Matthew Kane	C/O Precision Biosciences, Inc. 302 E. Pettigrew Street, Suite A-100 Durham NC 27701	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-05-07	21,514	$0.04	1,999,732	No	4	M	Direct
Common Stock	Disposition	2021-05-07	9,742	$8.57	1,989,990	No	4	S	Direct
Common Stock	Acquisiton	2021-05-10	21,514	$0.04	2,011,504	No	4	M	Direct
Common Stock	Disposition	2021-05-10	9,746	$8.25	2,001,758	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-05-07	21,514	$0.00	21,514	$0.04
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-05-10	21,514	$0.00	21,514	$0.04

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
43,028		2021-05-17	No	4	M	Direct
21,514		2021-05-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	10,841	Indirect	By Spouse

Footnotes

All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.31. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares are held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The option is fully vested and exercisable.